CHANGES IN LIVER STEATOSIS AFTER SWITCHING TO RALTEGRAVIR IN HIV/HCV COINFECTION

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2013 by Andaluz Health Service
Sponsor:
Information provided by (Responsible Party):
Juan Macías, Andaluz Health Service
ClinicalTrials.gov Identifier:
NCT01900015
First received: July 12, 2013
Last updated: July 15, 2013
Last verified: July 2013

July 12, 2013
July 15, 2013
November 2013
January 2015   (final data collection date for primary outcome measure)
To compare the impact of switching from EFV plus two nucleoside analogs to RAL plus two nucleoside analogs versus keeping the same antiretroviral regimen on HS as measured by CAP among HIV/HCV-coinfected patients. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01900015 on ClinicalTrials.gov Archive Site
To evaluate the proportion of patients who maintain viral control (HIV RNA < 50 copies/mL) after switching. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
CHANGES IN LIVER STEATOSIS AFTER SWITCHING TO RALTEGRAVIR IN HIV/HCV COINFECTION
CHANGES IN LIVER STEATOSIS AFTER SWITCHING FROM EFAVIRENZ TO RALTEGRAVIR AMONG HIV/HCV-COINFECTED PATIENTS RECEIVING TWO NUCLEOSIDE ANALOGS PLUS EFAVIRENZ: THE STERAL STUDY.

Primary Objective:

To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among HIV/HCV-coinfected patient.

Secondary Trial Objective:

  1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in the grade of HS between patients continuing with EFV plus two nucleoside analogs and those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside analogs.
  2. To evaluate the proportion of patients who maintain viral control (HIV RNA < 50 copies/mL) after switching.

Design:

Open-label, randomized clinical trial to evaluate safety (phase IV)

Condition:

HIV and HCV coinfection.

Intervention:

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Primary Objective:

To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among HIV/HCV-coinfected patient.

Secondary Trial Objective:

  1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in the grade of HS between patients continuing with EFV plus two nucleoside analogs and those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside analogs.
  2. To evaluate the proportion of patients who maintain viral control (HIV RNA < 50 copies/mL) after switching.

Design:

Open-label, randomized clinical trial to evaluate safety (phase IV)

Condition:

HIV and HCV coinfection.

Intervention:

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Study population and sample size HIV-infected patients with concomitant coinfection by HCV, as shown by detectable plasma HCV RNA, not candidates for therapy against HCV infection during the 48 week period of the Number of patients to recruit: 96, 48 patients per treatment group should be recruited.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HCV Coinfection
  • HIV Infection
  • Drug: Raltegravir
    Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
  • Drug: Efavirenz
  • Active Comparator: Raltegravir
    Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
    Intervention: Drug: Raltegravir
  • Active Comparator: Efavirenz
    Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
    Intervention: Drug: Efavirenz
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
96
January 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Each subject must be willing and able to provide written informed consent for the trial.
  2. Each subject must be ≥ 18 years of age.
  3. Each subject must be male or non-pregnant, non-breastfeeding female
  4. Each subject must have diagnosis of HIV infection.
  5. Each subject must have concomitant coinfection by HCV as shown by detectable plasma HCV RNA.
  6. Each subject must have stable treatment with EFV plus two nucleoside analogs for ≥24 weeks.
  7. Each subject must have at least 2 documented plasma HIV RNA <50 copies/ml during the last 24 weeks, as observed in, at least, two clinical visits.
  8. Each subject must have HS involving more than 10% of hepatocytes, as determined by a CAP measurement ≥238 dB/m.
  9. Each sexually active female subject of child-bearing potential must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 3 months after stopping the medication.Medically accepted methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, inert or copper-containing IUD, hormonereleasing IUD, systemic hormonal contraceptive, and surgical sterilization (eg,hysterectomy or tubal ligation).Postmenopausal women are not required to use contraception.Postmenopausal is defined as at least 12 consecutive months without a spontaneous menstrual period.
  10. Each sexually active male subject with a female partner(s) of child-bearing potential must also provide written informed consent to provide information regarding any pregnancy.
  11. Average daily alcohol intake lower than 50 g for men and 40 g for women.

Exclusion Criteria:

  1. The subject has an allergy/sensitivity to investigational product or its/their excipients.
  2. The female subject is nursing.
  3. The female subject is pregnant or intending to become pregnant.
  4. History of ARV failure or documented resistance.
  5. Baseline resistance to EFV or to any of the nucleoside analogues inhibitors in the regimen.
  6. The subject has any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.
  7. The subject has active AIDS-defining event (CDC-C) within 24 weeks before screening.
  8. The subject is candidate for therapy against HCV infection during the 48 week trial period in the opinion of the investigator.
  9. The subject has a history of malignant neoplasia.
  10. Active illicit drug use or any other condition that may compromise the study drug adherence in the opinion of the investigators.
  11. The subject has used any investigational drugs within 30 days of Baseline.
  12. A subject who has participated in any other clinical trial within 30 days,inclusive, of signing the informed consent form of the current trial.
  13. The subject or a family member is among the personnel of the investigational or SPONSOR staff directly involved with this trial.
Both
18 Years to 65 Years
Yes
Contact: Juan Macías, PhD 955015736 ext 315736 juan.macias.sanchez@gmail.com
Contact: María Mancebo, Nurse 955015871 ext 315871 marmanher86@gmail.com
Spain
 
NCT01900015
STERAL/50410
Yes
Juan Macías, Andaluz Health Service
Juan Macías
Not Provided
Principal Investigator: Juan Macías, MD, PhD Infectious Diseases and Microbiology Unit. Hospital Universitario de Valme. Servicio Andaluz de Salud
Andaluz Health Service
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP